Category: Injectable Medication

Amylin logo

EU Approves Type 2 Diabetes Drug Byetta for Use with Basal Insulin

The European Commission has granted marketing authorization to Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents...
0 Shares
Amylin Lilly Logo

Type 2 Diabetes Drug Byetta Recommended as Add-on Therapy to Insulin

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone)...
0 Shares
Amylin logo

FDA Approves Type 2 Diabetes Drug Bydureon

Amylin Pharmaceuticals, Inc. and Alkermes plc received FDA approval for Bydureon, a next generation once-weekly treatment for type 2 diabetes. The drug which received EU approval in June was turned down by the FDA twice during 2010, requesting further testing be conducted...
0 Shares
sanofi-logo

Positive Results for Sanofi’s Lyxumia in Treatment of Type 2 Diabetes

Sanofi announced positive results from the Gel Duo 1 study of it's investigational GLP-1 agonist, Lyxumia (lixisenatide) in the treatment of type 2 diabetes patients. The results show that patients with type 2 diabetes uncontrolled on oral anti-diabetics (OADs) – mainly metformin - significantly reduced their HbA1c levels when...
0 Shares